Clindamycin Phosphate; Tretinoin Patent Expiration
Clindamycin Phosphate; Tretinoin is Used for managing symptoms and inflammation associated with atopic dermatitis. It was first introduced by Bausch Health Us Llc
Clindamycin Phosphate; Tretinoin Patents
Given below is the list of patents protecting Clindamycin Phosphate; Tretinoin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veltin | US9492384 | Microemulsion and sub-micron emulsion process and compositions | Aug 31, 2025 | Almirall |
| Ziana | US6387383 | Topical low-viscosity gel composition |
Aug 03, 2020
(Expired) | Bausch |
| Ziana | USRE41134 | Slow release vehicles for minimizing skin irritancy of topical compositions |
Feb 24, 2015
(Expired) | Bausch |
| Veltin | US5690923 | Stable topical retinoid compositions |
Nov 25, 2014
(Expired) | Almirall |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clindamycin Phosphate; Tretinoin's patents.
Latest Legal Activities on Clindamycin Phosphate; Tretinoin's Patents
Given below is the list recent legal activities going on the following patents of Clindamycin Phosphate; Tretinoin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Apr, 2020 | US9492384 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Nov, 2016 | US9492384 |
| Recordation of Patent Grant Mailed Critical | 15 Nov, 2016 | US9492384 |
| Email Notification Critical | 27 Oct, 2016 | US9492384 |
| Issue Notification Mailed Critical | 26 Oct, 2016 | US9492384 |
| Dispatch to FDC | 17 Oct, 2016 | US9492384 |
| Application Is Considered Ready for Issue Critical | 14 Oct, 2016 | US9492384 |
| Issue Fee Payment Received Critical | 13 Oct, 2016 | US9492384 |
| Issue Fee Payment Verified Critical | 13 Oct, 2016 | US9492384 |
Clindamycin Phosphate; Tretinoin's Family Patents
Explore Our Curated Drug Screens
Clindamycin Phosphate; Tretinoin Generic API Manufacturers
Several generic applications have been filed for Clindamycin Phosphate; Tretinoin. The first generic version for Clindamycin Phosphate; Tretinoin was by Actavis Mid Atlantic Llc and was approved on Jun 12, 2015. And the latest generic version is by Encube Ethicals Private Ltd and was approved on Sep 1, 2023.
Given below is the list of companies who have filed for Clindamycin Phosphate; Tretinoin generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS MID ATLANTIC
Actavis Mid Atlantic Llc has filed for 1 generic for Clindamycin Phosphate; Tretinoin. This 1.2%;0.025% version comes by the name CLINDAMYCIN PHOSPHATE AND TRETINOIN. Given below are the details of the strengths of this generic introduced by Actavis Mid Atlantic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.2%; 0.025% | gel | Prescription | TOPICAL | AB1 | Jun 12, 2015 |
2. ENCUBE
Encube Ethicals Private Ltd has filed for 1 generic for Clindamycin Phosphate; Tretinoin. This 1.2%;0.025% version comes by the name CLINDAMYCIN PHOSPHATE AND TRETINOIN. Given below are the details of the strengths of this generic introduced by Encube.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.2%; 0.025% | gel | Prescription | TOPICAL | AB2 | Sep 1, 2023 |
Manufacturing Plant Locations New
Encube's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Encube as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| India |
| |||||
3. SOLARIS PHARMA CORP
Solaris Pharma Corp has filed for 1 generic for Clindamycin Phosphate; Tretinoin. This 1.2%;0.025% version comes by the name CLINDAMYCIN PHOSPHATE AND TRETINOIN. Given below are the details of the strengths of this generic introduced by Solaris Pharma Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.2%; 0.025% | gel | Prescription | TOPICAL | AB2 | Feb 10, 2022 |
Manufacturing Plant Locations New
Solaris Pharma Corp's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Solaris Pharma Corp as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||